SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-008871
Filing Date
2023-03-31
Accepted
2023-03-31 17:12:21
Documents
14
Period of Report
2023-03-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

Document Format Files

Seq Description Document Type Size
1 FORM 8-K sabs20230330_8k.htm   iXBRL 8-K 37361
2 PRESS RELEASE OF THE COMPANY, DATED MARCH 31, 2023 ex_495726.htm EX-99.1 26081
  Complete submission text file 0001437749-23-008871.txt   228624

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sabs-20230330.xsd EX-101.SCH 4177
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sabs-20230330_def.xml EX-101.DEF 14103
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE sabs-20230330_lab.xml EX-101.LAB 18628
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sabs-20230330_pre.xml EX-101.PRE 14125
8 EXTRACTED XBRL INSTANCE DOCUMENT sabs20230330_8k_htm.xml XML 4820
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 23789094
SIC: 2836 Biological Products, (No Diagnostic Substances)